MiNK Therapeutics, Inc. Common Stock (INKT)
MiNK Therapeutics, Inc. (INKT) is a biotechnology company focused on developing innovative immunotherapies and personalized treatments for cancer. The company leverages its proprietary technologies to enhance immune system responses, aiming to improve outcomes for patients with various types of malignancies.
Company News
MiNK Therapeutics reported a Q2 2025 net loss of $1.06 per share, with no revenue but promising clinical progress in iNKT cell therapies for cancer and immune diseases. The company raised $13 million in equity and continues advancing its lead product agenT-797 in clinical trials.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced its upcoming virtual Annual Shareholders Meeting and provided updates on its pipeline, including a NIAID grant for its allogeneic iNKT cell therapy for stem cell transplant patients and positive clinical data in various cancer indications.
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Technologies posted quarterly sales of $16.65 million, topping market estimates of $11.49 million, according to data from Benzinga Pro. The company als...
MiNK Therapeutics, Inc. (INKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How to trade penny stocks during a stock market crash The post 7 Strategies for Trading Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
